GeneDx Holdings Corp. (WGS)
WGSNASDAQ-GSMedical/Nursing Services
$54.83
-10.89 (-16.57%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $1.64bn
- P/E
- 365.5
- EPS, last 4 quarters
- $0.1500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $32.21 to $170.87
- Average volume
- 788.5k
- Previous close
- $65.72
Analysts
4 coveringBuy3 buy, 1 hold, 0 sell
Targets a year out average $93.00, +69.6% from here
Earnings
next estimate $0.3100Next report
Dec 2025
+27.3%
Mar 2026
-366.7%
Jun 2026
+105.3%
Sep 2026
+300.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $120.99m | $102.25m | $114.44m | $123.10m |
| Gross profit | $84.27m | $68.21m | $78.24m | $86.06m |
| Operating income | -$14.23m | -$57.47m | -$17.45m | -$10.43m |
| Net income | -$17.67m | -$63.32m | -$17.74m | -$12.33m |
Last four quarters: revenue $460.78m, margin -24.1%, free cash flow -$101.22m
News
8 latest- GeneDx (WGS) Q3 2026 Earnings Call TranscriptThe Motley Fool · 22 hours ago
- GeneDx Q3 Earnings Call HighlightsMarketBeat · 1 day ago
- GeneDx Holdings Corp. Reports Third Quarter 2026 Financial ResultsFintel · 1 day ago
- GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue EstimatesZacks · 1 day ago
- Noteworthy Monday Option Activity: HOOD, WGS, GRPNBNK Invest · 1 day ago
- Nutex Health Inc. (NUTX) Q3 Earnings and Revenues Beat EstimatesZacks · 5 days ago
- Agilon Health (AGL) Q3 Earnings and Revenues Surpass EstimatesZacks · 6 days ago
- Noteworthy Friday Option Activity: AVGO, DELL, WGSBNK Invest · Oct 23, 2026
The company
GeneDx's (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity - the world's largest rare disease genomic dataset. This unparalleled foundation powers GeneDx's ExomeDx and GenomeDx tests - ranked #1 by expert geneticists and granted FDA Breakthrough Device designation - enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine.
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- genedx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.